Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover.
Evaluation of: Zinman B, Haffner SM, Herman WH et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 95(1), 134-142 (2010). Until recently, patients with Type 2 diabetes were thought to be relatively protected against osteoporosis by their high BMI. However, recent epidemiological data suggest that fracture risk is increased in diabetic patients. Additionally, use of thiazolidinedione antidiabetic medications (rosiglitazone and pioglitazone) was unexpectedly found to be associated with an increased risk of fractures. The paper under evaluation in this article examines changes in biochemical markers of bone turnover in subjects within the clinical trial that first raised the issue of fractures. The main finding was a significant increase in bone resorption with rosiglitazone. This conclusion conflicts with other studies examining the effects of thiozolidinediones on bone and, by itself, is unlikely to fully explain the increased fracture risk seen with these drugs.